When again only considering those genes that also significantly correlate with a poor overall neuroblastoma patient survival, we identified 11 additional candidate dependency genes that were significantly differentially expressed (absolute log2 fold change threshold of 1 and adjusted p < 0.01) between TH-MYCN+/+ and wild-type mice exclusively at Week 6 compared to Week 1 (AGBL5, ATAD5, CHEK1, HDX, NEDD1, PABPC1, PHF19, POLD1, PYCR1, SMC2 and WNT5B) that were not identified as “MYCN-amplified/neuroblastoma” specific dependencies by the Avana CRISPR screen from the Depmap initiative. The gene discussed is AGBL5; the disease is neuroblastoma.